机译:肿瘤相关巨噬细胞作为术后阶段结肠癌患者术后辅助化疗的预后和预测生物标志物
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
174th Hosp PLA Xiamen Fujian Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Gen Surg Dept Shanghai Peoples R China;
机译:肿瘤相关巨噬细胞作为术后阶段结肠癌患者术后辅助化疗的预后和预测生物标志物
机译:根据预后因素对III期结肠癌患者进行术后辅助化疗的疗效
机译:缺陷错配修复状态作为接受FOLFOX辅助化疗的III期结肠癌患者无病生存的预后生物标志物。
机译:不应常规向患有阶段结肠癌的患者常规的辅助化学疗法,表明微卫星不稳定性
机译:基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
机译:Bcl-xL是不良的预后生物标志物特别是在BRAF突变的II期和III期结肠癌中对辅助化疗反应的预测因子
机译:肿瘤相关巨噬细胞作为术后阶段结肠癌患者术后辅助化疗的预后和预测生物标志物